Buprenorphine/Naloxone (Suboxone) Home Induction for People Living With HIV With Opioid Use Disorder
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
RWHAP Technical Assistance Provider updated on 05/28/2024
Blog updated 09/06/2022
This report highlights projects found to offer highly effective (and replicable) approaches to integrating buprenorphine-based medication-assisted treatment into HIV/AIDS primary care. Chapters outline the processes programs need to put in place, including meeting DATA 2000 regulatory requirements, achieving institutional buy-in, implementing staff training requirements, and evaluating processes and outcomes.
Resource updated 04/02/2024
Resource from the RWHAP Best Practices Compilation updated on 01/07/2024
Resource updated 04/08/2024
Resource from the RWHAP Best Practices Compilation updated on 01/07/2024
Resource updated 06/06/2024
Resource updated 09/14/2023
Blog updated 10/22/2021
Resource updated 10/24/2023
From HRSA's HIV/AIDS Bureau - 10/1/2021 - Dear Ryan White HIV/AIDS Program Colleagues:
From the HRSA HIV/AIDS Bureau Update: Special Bulletin - 10/5/21
A new FAQ has been added to the HRSA HIV/AIDS Bureau's Coronavirus Disease 2019 (COVID-19) Frequently Asked Questi
Next year’s Ryan White Conference will adopt an in-person/virtual format, while the Clinica